Con Call Highlights
-
Q3 occupancy lower due to many festivals etc in between which delays a lot of elective surgeries. Jan utilisation levels are higher and Q4 is likely to be materially higher than Q3
-
EBITDA breakeven for Asian Fidelis in 2 years. Likely ARPOB around Noida Hospital (currently at 25-30k range).
-
Jhansi Orcha is currently running at 6% EBITDA levels, to reach optimum utlisation capacity by next year (indicating big bump in next few quarters… since Q3 utilisation is around 22%)
-
Receivables has inched up mainly due to government side… but they are likely to be in control and release in the coming months
-
Robotic surgeries started in Greater Noida & Noida Extension and ARPOB is likely to inch up further in Q4. Radition oncology will also help that.
-
No EWS obligation on the hospital. Lands bought at market rates.
-
International patient ARPOB is higher. To get a boost once Noida airport starts (slated for end 2024 with 1 runway)
-
Tax was kept higher due to some conservative calculations, would normalise in subsequent few quarters
-
Brownfield expansions (Greater Noida & Noida Extension) to come up in next 1-2 years since the hospitals would reach the utilisation by then.
-
Confident of maintaining EBITDA % as in FY24 in the next year despite losses from Asian Fidelis (higher ARPOB is coming!)
Hoping for a bumper Q4 given higher ARPOBs and utilisation.
D – Invested
| Subscribe To Our Free Newsletter |
